UDP-glucuronosyltransferase 1A1*6 and *28 polymorphisms as indicators of initial dose level of irinotecan to reduce risk of neutropenia in patients receiving FOLFIRI for colorectal cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1437-7772
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
UDP-glucuronosyltransferase 1A1*6 and *28 polymorphisms as indicators of initial dose level of irinotecan to reduce risk of neutropenia in patients receiving FOLFIRI for colorectal cancer ; day:28 ; month:12 ; year:2015 ; pages:1-8
International journal of clinical oncology ; (28.12.2015), 1-8
- Creator
-
Miyata, Yoshinori
- Contributor
-
Touyama, Tetsuo
Kusumi, Takaya
Morita, Yoshitaka
Mizunuma, Nobuyuki
Taniguchi, Fumihiro
Manabe, Mitsuaki
SpringerLink (Online service)
- DOI
-
10.1007/s10147-015-0937-x
- URN
-
urn:nbn:de:1111-2016070422494
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:04 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Miyata, Yoshinori
- Touyama, Tetsuo
- Kusumi, Takaya
- Morita, Yoshitaka
- Mizunuma, Nobuyuki
- Taniguchi, Fumihiro
- Manabe, Mitsuaki
- SpringerLink (Online service)
Other Objects (12)
Etirinotecan pegol administration is associated with lower incidences of neutropenia compared to irinotecan administration
Risk of chemotherapy-induced febrile neutropenia in cancer patients receiving pegfilgrastim prophylaxis: does timing of administration matter?
Pro-inflammatory cytokine ratios determine the clinical course of febrile neutropenia in children receiving chemotherapy
Exploring Immune-Related Adverse Events: A Case of Febrile Neutropenia in a Melanoma Patient Receiving Immunotherapy
Synthesis of UDP-glucose, UDP-glucuronic acid and NRP luminmide using permeabilized cells
Prospective study of a molecular selection profile for RAS wild type colorectal cancer patients receiving irinotecan-cetuximab
Irinotecan-gut microbiota interactions and the capability of probiotics to mitigate Irinotecan-associated toxicity
UDP-Glucuronyltransferase
Structure : function relationship of UDP-sugar pyrophosphorylases
A prospective, real-world, multinational study of febrile neutropenia (FN) occurrence in oncology patients receiving chemotherapy with intermediate risk of FN: a MASCC Neutropenia, Infection, and Myelosuppression Study Group initiative
A prospective cohort study to evaluate the incidence of febrile neutropenia in patients receiving pegfilgrastim on-body injector versus other options for prophylaxis of febrile neutropenia: breast cancer subgroup analysis
Depletion of UDP-glucose and UDP-galactose using a Degron system leads to growth cessation of Leishmania major
Etirinotecan pegol administration is associated with lower incidences of neutropenia compared to irinotecan administration
Risk of chemotherapy-induced febrile neutropenia in cancer patients receiving pegfilgrastim prophylaxis: does timing of administration matter?
Pro-inflammatory cytokine ratios determine the clinical course of febrile neutropenia in children receiving chemotherapy
Exploring Immune-Related Adverse Events: A Case of Febrile Neutropenia in a Melanoma Patient Receiving Immunotherapy
Synthesis of UDP-glucose, UDP-glucuronic acid and NRP luminmide using permeabilized cells
Prospective study of a molecular selection profile for RAS wild type colorectal cancer patients receiving irinotecan-cetuximab
Irinotecan-gut microbiota interactions and the capability of probiotics to mitigate Irinotecan-associated toxicity
UDP-Glucuronyltransferase
Structure : function relationship of UDP-sugar pyrophosphorylases
A prospective, real-world, multinational study of febrile neutropenia (FN) occurrence in oncology patients receiving chemotherapy with intermediate risk of FN: a MASCC Neutropenia, Infection, and Myelosuppression Study Group initiative
A prospective cohort study to evaluate the incidence of febrile neutropenia in patients receiving pegfilgrastim on-body injector versus other options for prophylaxis of febrile neutropenia: breast cancer subgroup analysis
Depletion of UDP-glucose and UDP-galactose using a Degron system leads to growth cessation of Leishmania major
Etirinotecan pegol administration is associated with lower incidences of neutropenia compared to irinotecan administration
Risk of chemotherapy-induced febrile neutropenia in cancer patients receiving pegfilgrastim prophylaxis: does timing of administration matter?
Pro-inflammatory cytokine ratios determine the clinical course of febrile neutropenia in children receiving chemotherapy
Exploring Immune-Related Adverse Events: A Case of Febrile Neutropenia in a Melanoma Patient Receiving Immunotherapy
Synthesis of UDP-glucose, UDP-glucuronic acid and NRP luminmide using permeabilized cells
Prospective study of a molecular selection profile for RAS wild type colorectal cancer patients receiving irinotecan-cetuximab
Irinotecan-gut microbiota interactions and the capability of probiotics to mitigate Irinotecan-associated toxicity
UDP-Glucuronyltransferase
Structure : function relationship of UDP-sugar pyrophosphorylases
A prospective, real-world, multinational study of febrile neutropenia (FN) occurrence in oncology patients receiving chemotherapy with intermediate risk of FN: a MASCC Neutropenia, Infection, and Myelosuppression Study Group initiative
A prospective cohort study to evaluate the incidence of febrile neutropenia in patients receiving pegfilgrastim on-body injector versus other options for prophylaxis of febrile neutropenia: breast cancer subgroup analysis